Penumbra’s (PEN) “Hold” Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reaffirmed their hold rating on shares of Penumbra (NYSE:PEN – Free Report) in a research note published on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a $374.00 price target on the stock.

A number of other equities analysts have also recently issued reports on PEN. Zacks Research raised shares of Penumbra from a “strong sell” rating to a “hold” rating in a research report on Monday, August 24th. Weiss Ratings upgraded Penumbra from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, October 30th. Three analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $367.07.

Check Out Our Latest Analysis on PEN

Penumbra Stock Down 0.2%

Penumbra stock opened at $319.83 on Tuesday. The company has a quick ratio of 3.92, a current ratio of 5.89 and a debt-to-equity ratio of 0.01. Penumbra has a 12-month low of $277.54 and a 12-month high of $362.41. The firm’s fifty day moving average is $320.20 and its 200 day moving average is $325.33. The company has a market capitalization of $12.60 billion, a PE ratio of 81.17 and a beta of 0.71.

Penumbra (NYSE:PEN – Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $1.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.13). The company had revenue of $410.15 million for the quarter, compared to the consensus estimate of $401.41 million. Penumbra had a return on equity of 10.39% and a net margin of 10.06%. The firm’s revenue was up 15.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.97 earnings per share. As a group, sell-side analysts predict that Penumbra will post 4.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio purchased a new stake in Penumbra during the second quarter worth about $3,454,000. Engineers Gate Manager LP raised its position in Penumbra by 1,536.1% in the second quarter. Engineers Gate Manager LP now owns 15,003 shares of the company’s stock worth $4,737,000 after acquiring an additional 14,086 shares during the period. HBK Investments L P boosted its stake in Penumbra by 12.5% in the second quarter. HBK Investments L P now owns 1,838,508 shares of the company’s stock valued at $580,509,000 after acquiring an additional 204,247 shares during the last quarter. Odyssean LLC boosted its stake in Penumbra by 112.2% in the second quarter. Odyssean LLC now owns 9,328 shares of the company’s stock valued at $2,945,000 after acquiring an additional 4,932 shares during the last quarter. Finally, Sculptor Capital LP bought a new position in shares of Penumbra during the 1st quarter valued at approximately $18,717,000. Institutional investors and hedge funds own 88.88% of the company’s stock.

Penumbra Company Profile

(Get Free Report)

Penumbra, Inc. is a medical technology company that develops and markets devices for treating vascular conditions. Its products are used in neurovascular procedures, including the treatment of ischemic stroke and aneurysms, and in peripheral vascular procedures involving conditions such as pulmonary embolism and deep vein thrombosis. The company’s offerings include aspiration and mechanical thrombectomy systems, embolization coils, and related catheter-based devices. Penumbra was founded in 2004 and is headquartered in Alameda, California.

Featured Stories

Analyst Recommendations for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.